The FDA decision on BeiGene Ltd.’s (BGNE) Brukinsa in the expanded indication of treating adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma is due on January 20, 2023.Brukinsa is already approved by the FDA for the treatment of adult patients with Mantle cell lymphoma who have received at least one prior therapy, Waldenström’s macroglobulinemia, and relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen.The global product revenue of Brukinsa jumped to $155.5 million in the third quarter ended Sep.30, 2022, an increase of 136% over the year-ago quarter.BGNE closed Friday’s trading at $226.07, down 1.41%.